STANISLAO LAVORATO

STANISLAO LAVORATO

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NBNiccolò Bitto
Niccolò Bitto
GGGabriele Ghigliazza
Gabriele Ghigliazza
SLSTANISLAO LAVORATO
STANISLAO LAVORATO
CCCamilla Caputo
Camilla Caputo
VMVincenzo La Mura
Vincenzo La Mura
Portal hypertension is the consequence of cirrhosis and results from increased sinusoidal vascular resistance and hepatic blood inflow. Etiological therapies represent the first intervention to prevent a significant increase in portal pressure due to chronic liver damage. However, other superimposed pathophysiological drivers may worsen liver disease, including inflammation, bacterial translocation, endothelial dysfunction, and hyperactivation of hemostasis. These mechanisms can be targeted by a specific class of drugs already used in clinical practice. Albumin, rifaximin, statins, aspirin, and anticoagulants have been tested in cirrhosis and were a topic of discussion in the last Baveno consensus as non-etiological therapies. Based on the pathogenesis of portal hypertension in cirrhosis, our review summarizes the main mechanisms targeted by these drugs as well as the clinical evidence that considers them a valid complementary option to manage patients with cirrhosis and portal hypertension.